logo
  

China Automotive Systems Q4 Net Income Rises, Net Sales Up 23.6%; Issues Revenue Guidance

China Automotive Systems, Inc. (CAAS) reported that its fourth quarter net income attributable to parent company's common shareholders increased by 153.5% to $10.9 million, or net income per share of $0.36, compared to net income of $4.3 million, or net income per share of $0.14, a year ago.

Net sales increased by 23.6% year-over-year to $159.2 million. The company said the net sales increase was mainly due to a change in the product mix and higher demand for passenger automobiles and commercial vehicles in the fourth quarter of 2023 compared to the fourth quarter of 2022.

The company expects revenue for fiscal 2024 of $605.0 million.

As of December 31, 2023, total cash and cash equivalents, pledged cash and short-term investments were $166.3 million.

Shares of China Automotive Systems are up 8% in pre-market trade on Thursday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, Kraft Heinz Co. (KHC) reaffirmed its adjusted earnings and organic net sales growth guidance for the full-year 2024. For fiscal 2024, the company still projects adjusted earnings in a range of $3.01 to $3.07 per share on organic... While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook. For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from... While reporting financial results for the first quarter on Wednesday, CVS Health (CVS) slashed its earnings and adjusted earnings guidance for the full-year 2024, reflecting the potential for continued elevated medical cost trends in the remainder of 2024. For fiscal 2024, the company now projects...

This week, we feature OJEMDA’s FDA approval, Bristol Myer’s Job cuts, Novo Nordisk’s increased pricing of drugs in US, Incyte’s strategic acquisition, and Ireland’s Alcohol labels.

View More Videos
Follow RTT